폴리피드PYPD 주가

PolyPid to Participate in the Craig-Hallum 23rd Annual Institutional Investor Conference

PETACH TIKVA, Israel, May 20, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced that the Company’s management will participate in investor meetings at the Craig-Hallum 23rd Annual Institutional Investor Conference on Thursday, May 28, 2026, at the Depot Renaissance Hotel in Minneapolis, MN. Investors intere

PolyPid Ltd (PYPD) Q1 2026 Earnings Call Highlights: Strategic Advances Amid Financial Challenges

PolyPid Ltd (PYPD) progresses with NDA submission and strategic partnerships, despite reporting a net loss and decreased cash reserves.

♻️ 재탕PolyPid Ltd. Q1 2026 Earnings Call Summary

Moby summary of PolyPid Ltd.'s Q1 2026 earnings call

PolyPid (PYPD) Q1 2026 Earnings Transcript

Yehuda Leibler: Thank you, operator, and thank you all for joining PolyPid's First Quarter 2026 Earnings Conference Call. Joining me on the call today will be Dikla Czaczkes Akselbrad, Chief Executive Officer of PolyPid; Jonny Missulawin, PolyPid's Chief Financial Officer; and Ori Warshavsky, Chief Operating Officer, U.S. of PolyPid.

PolyPid Q1 Earnings Call Highlights

PolyPid (NASDAQ:PYPD) said its first quarter marked a transition from late-stage clinical development toward regulatory submission and commercial preparation for D-PLEX100, its lead product candidate for preventing surgical site infections in abdominal colorectal surgery. Chief Executive Officer Di

♻️ 재탕PolyPid Q1 2026 Earnings Call: Complete Transcript

PolyPid (NASDAQ:PYPD) held its first-quarter earnings conference call on Wednesday. Below is the complete transcript from the call. This content is powered by Benzinga APIs. For comprehensive financial data and transcripts, visit https://www.benzinga.com/apis/. The full earnings call is available at https://edge.media-server.com/mmc/p/w3mvdb4o/ Summary PolyPid reported a net loss of $7.7 million for Q1 2026, an improvement from a loss of $8.3 million in Q1 2025, with operating expenses showing a

♻️ 재탕PolyPid Ltd. (PYPD) Q1 2026 Earnings Call Transcript

Transcript : PolyPid Ltd., Q1 2026 Earnings Call, May 13, 2026

Presentation Operator MessageOperator Greetings, and welcome to PolyPid's First Quarter 2026 Earnings Conference Call. [Operator Instructions] As a reminder, this call is recorded. And I would now...

PolyPid Provides Corporate Update and Reports First Quarter 2026 Financial Results

Initiated NDA Submission to the FDA for D-PLEX₁₀₀ ; Completion Expected Imminently U.S. Commercial Partnership Discussions in Late Stages Conference Call Scheduled for Today at 8:30 AM ET PETACH TIKVA, Israel, May 13, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today provided a corporate update and reported financial

Earnings Scheduled For May 13, 2026